A. J.  Kazimi net worth and biography

A. J. Kazimi Biography and Net Worth

Mr. Kazimi founded our company in 1999 and has served as the Chairman of our Board of Directors and Chief Executive Officer since inception. His career includes 30 years in the biopharmaceutical industry. At Cumberland, he has overseen the development and FDA approval of the company’s Acetadote® and Caldolor® brands, while also leading the acquisition of the Company’s five other commercial products. He was responsible for Cumberland’s initial public offering and listing on the NASDAQ stock exchange. He also serves as Chairman and Chief Executive of Cumberland Emerging Technologies. Prior to joining our company, he spent eleven years helping to build Therapeutic Antibodies Inc., an international biopharmaceutical company.

As President and Chief Operating Officer, he made key contributions to that company’s growth from its start-up phase through its initial public offering and listing on the London stock exchange. Mr. Kazimi started his career at Brown-Forman Corporation, rising through a series of management positions and helping to launch several new products. Mr. Kazimi serves on the Board of Directors for the Nashville Health Care Council, an association of the largest concentration of healthcare companies in the U.S. He also serves on the Boards of the Tennessee Historical Society and the Gettysburg Foundation which partners with the National Park Service to preserve the historic military park.

Mr. Kazimi is a member of the Board of Visitors at the Vanderbilt University Business School and the Visiting Committee at the Loyola University New Orleans’ College of Business. He previously served on the board of Aegis Sciences Corporation, a federally certified forensic toxicology laboratory, which has sold twice to large private equity investors. He holds a B.S. from the University of Notre Dame and an M.B.A. from the Vanderbilt University Owen Graduate School of Management. 

What is A. J. Kazimi's net worth?

The estimated net worth of A. J. Kazimi is at least $6.58 million as of April 16th, 2021. Mr. Kazimi owns 5,767,734 shares of Cumberland Pharmaceuticals stock worth more than $6,575,217 as of November 5th. This net worth evaluation does not reflect any other assets that Mr. Kazimi may own. Additionally, Mr. Kazimi receives an annual salary of $952,530.00 as CEO at Cumberland Pharmaceuticals. Learn More about A. J. Kazimi's net worth.

How old is A. J. Kazimi?

Mr. Kazimi is currently 66 years old. There are 6 older executives and no younger executives at Cumberland Pharmaceuticals. Learn More on A. J. Kazimi's age.

What is A. J. Kazimi's salary?

As the CEO of Cumberland Pharmaceuticals Inc., Mr. Kazimi earns $952,530.00 per year. Learn More on A. J. Kazimi's salary.

How do I contact A. J. Kazimi?

The corporate mailing address for Mr. Kazimi and other Cumberland Pharmaceuticals executives is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. Cumberland Pharmaceuticals can also be reached via phone at (615) 255-0068 and via email at [email protected]. Learn More on A. J. Kazimi's contact information.

Has A. J. Kazimi been buying or selling shares of Cumberland Pharmaceuticals?

A. J. Kazimi has not been actively trading shares of Cumberland Pharmaceuticals in the last ninety days. Learn More on A. J. Kazimi's trading history.

Who are Cumberland Pharmaceuticals' active insiders?

Cumberland Pharmaceuticals' insider roster includes Martin Cearnal (SVP), Joseph Galante (Director), A. J. Kazimi (CEO), A.J. Kazimi (CEO), Kenneth Krogulski (Director), and William Sumas (EVP). Learn More on Cumberland Pharmaceuticals' active insiders.

A. J. Kazimi Insider Trading History at Cumberland Pharmaceuticals

See Full Table

A. J. Kazimi Buying and Selling Activity at Cumberland Pharmaceuticals

This chart shows A J. Kazimi's buying and selling at Cumberland Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cumberland Pharmaceuticals Company Overview

Cumberland Pharmaceuticals logo
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Read More

Today's Range

Now: $1.14
Low: $1.10
High: $1.20

50 Day Range

MA: $1.27
Low: $1.12
High: $1.39

2 Week Range

Now: $1.14
Low: $1.07
High: $2.36

Volume

29,439 shs

Average Volume

12,689 shs

Market Capitalization

$16.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22